Catalyst Wire Dossier Catalyst Wire Dossier

Candesartan/Hydrochlorothiazide

candesartan/hydrochlorothiazide · AstraZeneca
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Candesartan/Hydrochlorothiazide, covering 2008-02-06 to 2008-03-20. Get the full timeline:

Most recent: Clinical Trial Update: Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg [Phase 3]

See pricing